Women’s health remains an underserved area in modern medicine, especially in conditions rooted in ovarian dysfunction. Despite the prevalence of hormonal imbalances—affecting one in three women worldwide—treatment protocols have changed little over the past five decades. Traditional hormonal interventions often provide temporary relief but fail to address the root cause of ovarian-related conditions, which range from PCOS to endometriosis. Celmatix is addressing this challenge by targeting the core of women’s health: the ovary. The company has built the largest structured dataset on ovarian health and outcomes, which it uses to decode the complex signaling networks governing ovarian function. This data powers Celmatix’s proprietary multi-omics platform, a foundation for groundbreaking drug development programs aimed at radically improving the quality of care for millions of women.

Innovative Therapeutic Programs

Celmatix’s therapeutic pipeline is anchored in science and innovation, targeting unmet needs in reproductive and hormonal health.

• Oral FSHR Agonist Program: The Company’s lead oral Follicle Stimulating Hormone Receptor (FSHR) agonist program is a breakthrough in fertility treatment. Historically, fertility treatments have relied on injectable drugs, which can be costly and invasive. Celmatix’s novel oral FSHR agonist aims to simplify fertility care for both men and women, offering a less invasive, patient-friendly solution with significant market potential.

• PCOS and Endometriosis Drug Programs: Celmatix is leveraging its expertise in reproductive biology to target melatonin receptors outside the central nervous system (CNS). This program focuses on developing first-line treatments for PCOS, a condition affecting 1 in 10 women globally, and endometriosis, which has remained notoriously underfunded and understudied. The melatonin receptor agonists in development promise effective, non-hormonal treatments for these debilitating conditions.

• Ovarian Senescence (OS) Program: Celmatix’s flagship program tackles ovarian senescence, a condition that impacts endocrine health as women age. Chemotherapy-induced ovarian failure and conditions such as Mosaic Turner Syndrome and FMR1-related primary ovarian insufficiency (POI) are among the targets. This program represents a potential breakthrough in both oncology and reproductive health.

Breakthroughs and Strategic Partnerships

Celmatix’s success is underpinned by its robust multi-omics platform and strategic collaborations.

Proprietary Multi-Omics Platform:

• Cohorts and Data: Celmatix’s datasets include treatment histories, genomic information, and biological samples from over half a million individuals.

• Annotations: The Company’s proprietary annotations are continuously updated with natural language processing (NLP) models that predict the relevance of new studies.

• Research Tools: A cutting-edge annotation platform powers clinical validity scores and phenotype classifications for drug discovery.

Key Collaborations:

• Evotec Partnership: Celmatix’s five-year collaboration with Evotec focuses on identifying drug targets for high-need conditions like PCOS and endometriosis. As part of this partnership, Bayer AG has contributed resources to advance drug discovery and development.

• Personalized Reproductive Medicine Initiative: Celmatix collaborates with 15 U.S.-based reproductive health centers, collecting biological samples paired with extensive medical histories. This initiative has fueled discoveries that power Celmatix’s drug programs.

• Bill & Melinda Gates Foundation: With the Foundation’s support, Celmatix is identifying novel targets for next-generation female contraceptives, addressing the unmet need for effective, accessible solutions in low- and middle-income countries.

• Aché Laboratórios: Celmatix recently partnered with Brazilian pharmaceutical company Aché Laboratórios to explore melatonin receptor agonists for conditions like PCOS. This collaboration aligns with Celmatix’s strategy to expand its footprint in global women’s health innovation.

Recent Milestones

• $3.5 Million ARPA-H Award (October 2024): Celmatix was awarded $3.5 million by the Advanced Research Projects Agency for Health (ARPA-H) through its Sprint for Women’s Health initiative. This funding supports early-stage research into transformative solutions for women’s health challenges.

• First Lead Compound in Fertility Drug Program (October 2024): The company announced its first lead compound in the oral FSHR agonist program during the American Society for Reproductive Medicine (ASRM) annual meeting, signaling a major milestone in fertility innovation.

• Largest Genetic Study on Endometriosis (March 2023): Celmatix partnered with the University of Oxford and 24 global institutions to publish the largest-ever genetic study on endometriosis in Nature Genetics. This study, which analyzed data from over 760,000 women, provides invaluable insights into the condition’s genetic basis.

Leadership Driving Impact

Piraye Yurttas Beim, PhD – Founder & CEO:

A visionary in women’s health innovation, Dr. Beim founded Celmatix after completing her PhD at Cornell University and Memorial Sloan Kettering Cancer Center. Inspired by the transformative power of genomics in oncology, she applied these principles to reproductive health, establishing Celmatix to fill critical gaps in care. With over 20 years of experience, Dr. Beim remains at the forefront of women’s health advocacy and innovation.

Industry Impact

Celmatix’s efforts transcend the boundaries of traditional medicine, offering holistic solutions for reproductive and hormonal health. By decoding ovarian function and building data-driven therapies, Celmatix is reshaping the standard of care for women. Its innovations, from oral fertility drugs to melatonin receptor agonists, are poised to address long-standing challenges in women’s health, providing more effective and personalized treatment options. With an unwavering commitment to innovation, robust partnerships, and a data-rich platform, Celmatix is not just developing new drugs—it’s pioneering a new era in women’s health.

Piraye Yurttas Beim, PhD, Founder & CEO

"Our mission at Celmatix is to transform the landscape of women's health by leveraging cutting-edge science and technology."